Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China,Journal of Hematology & Oncology

当前位置： X-MOL 学术 › J. Hematol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China
Journal of Hematology & Oncology ( IF 29.5 ) Pub Date : 2021-08-23 , DOI: 10.1186/s13045-021-01139-6
Jie Zha _{1,

2} , Liyuan Fan _{1,

2} , Shuhua Yi ₃ , Haifeng Yu _{4,

5} , Zhong Zheng ₆ , Wei Xu ₇ , Manman Deng _{1,

2} , Zhijuan Lin _{1,

2} , Zhifeng Li _{1,

2} , Lingyan Ping ₈ , Xiaohua He _{9,

10,

11} , Feili Chen ₁₂ , Ying Xie ₁₃ , Biyun Chen ₁₃ , Huilai Zhang ₁₄ , Li Wang ₇ , Kaiyang Ding ₁₅ , Wenyu Li ₁₂ , Haiyan Yang _{4,

5} , Weili Zhao ₆ , Lugui Qiu ₃ , Zhiming Li _{9,

10,

11} , Yuqin Song ₈ , Bing Xu _{1,

2}

Affiliation

Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China.
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital and Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Department of Lymphoma, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Lymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Shengli Clinical Medical College of Fujian Medical University, Department of Hematology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China.
Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China.
Department of Hematology, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, China.

Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationwide in China. In this cohort, the median age of patients at diagnosis was 53 years, which was comparable to that reported previously for Chinese FL patients (49–51 years) but younger than that for Western FL patients (60–65 years). In contrast with Western patients, Chinese FL patients more likely involved extranodal sites but less frequently infiltrated bone marrow. Other clinical characteristics were comparable between two populations. In this study, 91% of patients were managed with chemotherapy, yielding 72% and 46% of overall-response rate and complete remission. After median 55-month follow-up, 5-year progressive-free and overall survival were 61% and 89%, respectively. Both were analogous to those reported in prior Chinese and Western studies. Consistent with published data, addition of rituximab into both induction (Ri) and maintenance (Rm) treatment led to the most favorable outcomes. Interestingly, Ri only had better outcomes than Rm only. Notably, 7% of patients experienced histologic transformation (HT) and correlated with poor survival. Of the transformed FL cases, 3% and 4% of HT events occurred prior to or post-treatment, respectively. Importantly, the latter displayed worse outcomes than the former. Altogether, this study provides real-world information of the largest cohort of FL patients so far in China, which might lay a foundation for clinical investigation of Chinese FL in future.

更新日期：2021-08-23

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11